Join Pharma | Login

	Editorial


	An Ill-informed Policy
	Wednesday, April 30, 2025
	In a controversial decision which has literally opened a Pandora's box, the Gujarat government has recently introduced a new differential pricing policy, which was later withdrawn, for the Drug-Eluting Stents (DES)
	Past Editorial...

TODAY'S NEWS


18:00 [IST]	Gifthealth appoints Chip Parkinson as CEO to accelerate growth and innovation in pharmacy services
17:00 [IST]	US FDA grants fast track designation to OKYO Pharma’s urcosimod to treat neuropathic corneal pain
16:00 [IST]	Sanofi to showcases leadership and breadth of scientific innovation in chronic inflammatory respiratory conditions at ATS conference
15:00 [IST]	Nexalin Technology initiates US FDA Q-Submission process for Gen-2 SYNC system
14:30 [IST]	Zydus Lifesciences completes 25 years of listing on NSE, commemorated with a bell ringing ceremony at NSE
14:00 [IST]	Element Science receives US FDA approval for revolutionary Jewel Patch Wearable Cardioverter Defibrillator

more news >>

TOP NEWS


08:00 [IST]	High Court quashes IPO's decision to hear pre-grant opposition after signing patent approval
08:00 [IST]	India’s Healthtech boom faces tough test to balance personalisation and data privacy: Vineet Mehta
08:00 [IST]	CDSCO revises public hearing schedule for various divisions
08:00 [IST]	Upcoming B Pharm curriculum will overhaul pharmacy education at graduate level: Experts
08:00 [IST]	DGFT eases pharma export rules for SCOMET items for testing and evaluation
08:00 [IST]	CDSCO adds tooltips in its online platforms for legal forms to support stakeholders

more news >>

YESTERDAY'S NEWS


18:00 [IST]	JediCare Medical completes first-in-human feasibility study of world's first-of-its-kind pulmonary nodule percutaneous sphere resection
17:00 [IST]	Addex inks agreement with Sinntaxis for an exclusive license to IP covering the use of mGlu5 inhibitors in brain injury recovery
16:00 [IST]	PL BioScience introduces patented gamma-irradiated Human Platelet Lysate, ELAREM Ultimate-FD PLUS
15:45 [IST]	Lifesigns and Cura Hospital bridge urban-rural healthcare gap with AI-enabled care
15:00 [IST]	Genocury Biotech announces positive results from noval in vivo CD19 CAR-T therapy in relapsed/refractory diffuse large B-cell lymphoma
14:15 [IST]	Apollo Diagnostics revolutionizes diagnostics with Digi-Smart Lab

more news >>

INTERVIEW


All DIs in TN are fully competent to inspect manufacturing units as per Revised Schedule M: MN Sridhar
MN Sridhar, director of the Tamil Nadu Drugs Control Department

Past Interviews...

	What's New?

Syngene’s revenue from operations crossed Rs. 1,000 crore mark in Q4, PAT dips by 3%, full year earnings up 4% to Rs. 3,642 crore Methotrexate 2.5 Mg Tab/cap Fluvoxamine 100mg Tab Vitamin D3 Inj -600000 Iu-1 Ml. Tab Tianeptine 12.5 Mg

Opinion Poll

Will the introduction of Revised Schedule M by Union Health Ministry solve the issue of quality of Indian drugs?

YesNoCan't Say

View Past Poll

Corporate

Special Features

Features

Chronicle Pharmabiz Specials

Forthcoming Events

TENDERS & PROJECTS

	Tenders & Enquiries
	Pharma Projects

CORPORATE

	Company Profile
	Corporate Results
	Corporate X-ray
	Pharmabiz Studies of Top Companies

US FDA UPDATE

EXPORT & IMPORT

	Drug Export Procedures
	Drug Units With WHO GMP Certification
	Pharma Export Data
	Import Reg. Update

PHARMA LAWS & DOCUMENTS

LIST OF LABS & GOVT. BODIES

	Govt Recognised In-House R&D Units
	AICTE Boards & Committees
	List of Indian CROs
	List of CROs (International)
	Govt & approved labs of India
	List of State Drugs Controllers